List of Tables
Table 1: Orphan and Rare Dermatology Drugs Market, Global, Symptoms of the Key Indications, 2018 15
Table 2: Orphan and Rare Dermatology Drugs Market, Global, Etiology of the Key Indications, 2018 20
Table 3: Orphan and Rare Dermatology Drugs Market, Global, Prognosis for Epidermolysis Bullosa, 2018 30
Table 4: Orphan and Rare Dermatology Drugs Market, Global, Key Marketed Products and Approved Indications, 2018 37
Table 5: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Humira, 2018 38
Table 6: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Ilaris, 2018 40
Table 7: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Afinitor, 2018 42
Table 8: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Kineret, 2018 44
Table 9: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Arcalyst, 2018 46
Table 10: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Tracleer, 2018 48
Table 11: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Thalomid, 2018 50
Table 12: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Methylprednisolone, 2018 54
Table 13: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Meticorten, 2018 56
Table 14: Orphan and Rare Dermatology Drugs Market, US, Approved Orphan and Rare Dermatology Indications for Rayos, 2018 56
Table 15: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2017–2024 84
Table 16: Orphan and Rare Dermatology Drugs Market, Global, Forecast Revenue by Company (%), 2017–2024 93